“Cara announced this morning that the company has completed an End of Phase 2 mtg with FDA around CR845 in Pruritus associated with Chronic Kidney Disease. We spoke w/ mgmt for an update. Cara plans to initiate one Phase 3 trial of IV CR845 in the U.S. in 4Q17, followed by a second Phase 3 trial in Europe in early 2018. Details on size and design are expected during 3Q17 conference call in a few wks. Although mgmt not providing guidance on timing to top-line results, we believe NDA submission YE19 and launch YE20 still appears feasible.”,” the firm’s analyst commented.
Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut Regeneron Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, October 10th. Morgan Stanley reiterated an equal weight rating and issued a $490.00 price objective (up previously from $450.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. Jefferies Group LLC reiterated a hold rating and issued a $500.00 price objective (up previously from $471.00) on shares of Regeneron Pharmaceuticals in a report on Friday, October 6th. SunTrust Banks, Inc. reiterated a hold rating and issued a $435.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday, October 2nd. Finally, Piper Jaffray Companies reiterated an overweight rating and issued a $540.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, September 29th. Three investment analysts have rated the stock with a sell rating, fourteen have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of Hold and a consensus target price of $489.92.
Regeneron Pharmaceuticals (NASDAQ:REGN) opened at 439.37 on Monday. Regeneron Pharmaceuticals has a 1-year low of $325.35 and a 1-year high of $543.55. The firm has a market capitalization of $46.59 billion, a price-to-earnings ratio of 44.08 and a beta of 1.62. The company has a 50 day moving average price of $454.22 and a 200-day moving average price of $456.52.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the consensus estimate of $2.67 by $1.50. The company had revenue of $1.47 billion during the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. Regeneron Pharmaceuticals’s quarterly revenue was up 21.2% compared to the same quarter last year. During the same period in the prior year, the business posted $2.82 EPS. On average, analysts forecast that Regeneron Pharmaceuticals will post $14.94 EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals, Inc. (REGN) Earns Buy Rating from Canaccord Genuity” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://stocknewstimes.com/2017/10/19/regeneron-pharmaceuticals-inc-regn-earns-buy-rating-from-canaccord-genuity.html.
In other news, CFO Robert E. Landry sold 189 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the sale, the chief financial officer now directly owns 10,099 shares of the company’s stock, valued at $5,060,204.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Robert E. Landry sold 526 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, August 8th. The stock was sold at an average price of $472.19, for a total value of $248,371.94. Following the completion of the sale, the senior vice president now directly owns 9,099 shares in the company, valued at $4,296,456.81. The disclosure for this sale can be found here. Insiders sold 89,468 shares of company stock worth $42,312,448 over the last 90 days. Company insiders own 10.80% of the company’s stock.
Several hedge funds have recently modified their holdings of REGN. Fieldpoint Private Securities LLC bought a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $130,000. Sterling Investment Advisors Ltd. increased its holdings in shares of Regeneron Pharmaceuticals by 11.2% in the second quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $140,000. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% in the second quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Finally, Alpha Windward LLC increased its holdings in shares of Regeneron Pharmaceuticals by 0.3% in the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 1 shares during the last quarter. 67.40% of the stock is currently owned by hedge funds and other institutional investors.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.